Fig. 5.

Pre-treatment with rHSP27 does not enhance the migration capabilities of tumor HeLa cells. The migration was assayed using transwell analysis. Five fields were obtained from each well, and then the migrating cells were counted using ImageJ software and then analyzed. HeLa cells were seeded, attached for 12 h, and then treated as indicated. Line 1: basal control represents cells without any treatment (upper and lower chamber), Line 2: cells without any treatment (Cd 0) in the upper chamber and media +10% SFB in the lower chamber. Line 3: cells treated with Cd (50 μM Cd in DMEM upper chamber) for 24 h and media +10% SFB in the lower chamber. Lines 4 and 5: cells were pre-treated with rHSP27 (100 μg/ml) for 12 h (upper chamber) and then exposed to the indicated Cd concentration for 24 h (upper chamber and media +10% SFB in the lower chamber). Lines 6 and 7: cells were pre-treated with rC1 for 12 h (100 μg/ml) in the upper chamber and then exposed to the indicated Cd concentration for 24 h in the upper chamber and media +10% SFB in the lower chamber. The data were expressed as means ± S.D. *p < 0.05; **p < 0.01; ***p < 0.001 vs control